PTSD

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.

Bionomics announced the release of the full dataset analysis of the ATTUNE phase 2b trial; the data suggests BNC210 for PTSD could have an advantage over approved medications.

A new study found crisis response planning for PTSD among military veterans had lower onset of suicidal ideation than veterans with self-guided safety planning.

A new study found that 25% of PSG-PTSD were related to metabolic traits.

Participants with PTSD in a new study heard voices more significantly than did patients with schizophrenia and schizoaffective disorder, according to investigators.

Investigators systematically review data to further understand the relationship between sleep and PTSD as it impacts treatment outcomes.